now made my contribution of simple mastectomy cases to the trial, I feel free to resume partial mastectomy. It is of interest to note that, in this published series, there was one patient who presented 15 years ago with bilateral primary breast cancer. The right side was treated by partial mastectomy followed by irradiation because the tumour was situated in the inner upper quadrant; the cancer in the left breast was slightly smaller and situated in the outer half and it was treated by partial mastectomy only. She remains well and free from recurrence 15 years later. This is an anecdotal case, but I believe the time has now come when we are ethically justified in planning a trial of partial mastectomy, with and without postoperative irradiation to the breast only, as an alternative to mastectomy. Experience during recent years has shown that both good local control and a surprisingly high percentage of five-year survivals can follow irradiation treatment of even locally advanced breast cancers. The essential factor, if good results are to be obtained, is adequatei.e. highdosage of radiation. At the same time, painful skin reactions in the large areas needing to be covered must be avoided. Supervoltage radiation can be used to spare the skin, provided there is not wide skin involvement. As this is commonly present in advanced cases, full skin dosage is often necessary. By means of a split-course technique painful reactions can be avoided, even with orthovoltage radiation to high dosage. The tolerance limit with continuous fractionation is around 4250 R over three weeks, but this failed to sterilize the tumour in nearly all cases so treated.
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In 33 patients treated by two-part split-course to an average of 5300 R (at 250 kV) in 14 fractions over four weeks, with a four-week rest peiiod, local control by radiation alone was achieved in 13 cases. In 12 others the tumour became operable. Identifiable cancer cells were seen in all mastectomy specimens, but local recurrence followed in only 4 patients.
In 14 patients (all Stage T3 or T4) treated by three-part split-course, to average tumour dose of 7000 R in 16 fractions over five weeks plus two rest periods, the tumour was controlled locally in 8 patients throughout their subsequent history. No carcinoma cells were identifiable in 4 of these who later underwent mastectomy. In 4 other patients the tumours became operable, but had not been histologically sterilized.
Four patients survived for over five years; 2 are alive and well at eight years. Two patients survived 'three years; one, who survived two years, died from metastases without local recurrence.
In spite of high dosage, delivered by 250 kV X-rays, skin reactions were very mild in 6 cases, moderate in 6 and severe in only 2.
Miss M D Snelling (Meyerstein Institute ofRadiotherapy, The Middlesex Hospital, London WIN8AA)
Experiences ofFrench Radiotherapists [Abstract]
An account was given of work carried out by French radiologists -this has been reported by Dr Calle of the Fondation Curie and also by other radiotherapists in the press and at a symposium on the 'conservative' treatment of carcinoma of the breast (i.e. the treatment of carcinoma of the breast without mastectomy). These radiotherapists report excellent results of the treatment of TINo carcinoma by local excision followed by radiotherapy. A tumour dose of 8000 rad or more is given to the primary area at these centres while the normal glands receive a dose of 6000 or 7000 rad. The use of radiotherapy in more advanced cases was also describedthe most important critical local structure is the brachial plexus. Survival of T1 and early T2 cases at five years is reported as approximately 75% and local cure without mastectomy in about 60%. Failures were due almost always to metastases. Cosmetic results were excellent in at least one-half of the patients.
